Clinical Trial Detail

NCT ID NCT04201457
Title A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Pediatric Brain Tumor Consortium
Indications

malignant glioma

Therapies

Hydroxychloroquine + Trametinib

Dabrafenib + Hydroxychloroquine + Trametinib

Age Groups: child adult

Additional content available in CKB BOOST